Skip to main content

Table 2 Binding score of each selected peptide for the HLA specificities evaluated

From: Computer-Based Design of an HLA-Haplotype and HIV-Clade Independent Cytotoxic T-Lymphocyte (CTL) Assay for Monitoring HIV-Specific Immunity

 

HLA-A

HLA-B

HLA-C

Peptides

A1

A2

A3

A24

A31

A33

A68

B7

B8

B14

B15

B27

B35

B37

B38

B39

B40

B44

B51

B52

B58

B60

B61

B62

Cw3

Cw4

Cw6

Cw7

1.1: EKIRLRPGGKKKYRL

40

42

81

8

40

40

45

70

88

11

26

37

45

18

11

1.2a: PGGKKKYRLKHLVWA

20

41

33

6

34

77

12

32

46

9

27

10

10

10

10

10

7

1.2b: PGGKKKYRMKHLVWA

20

41

33

10

34

52

10

35

46

27

10

10

10

10

10

7

1.3a: KKYRLKHLVWASREL

14

61

37

6

33

10

12

29

40

6

42

43

10

42

45

12

15

11

8

45

11

1.3b: KKYRMKHLVWASREL

14

61

37

6

66

10

12

29

40

6

42

38

10

42

45

12

15

11

8

45

11

1.4: KHLVWASRELERFAV

26

33

46

33

74

37

35

42

38

42

15

45

10

57

8

45

1.5a: RELERFAVNPGLLET

46

61

48

25

6

31

38

45

45

70

12

50

12

39

63

31

18

75

60

8

52

1.5b: RELERFAVDPGLLET

46

58

48

25

34

38

45

42

70

12

50

12

37

63

31

18

75

60

6

52

2.1a: SAPKTGTEELRSLYN

68

47

26

10

18

68

63

45

38

83

47

55

65

67

45

27

2.1b: SALKTGTEELRSLYN

68

47

26

10

18

68

63

45

38

83

47

55

65

67

45

6

27

2.2: EELRSLYNTVATLYC

18

86

53

33

6

37

44

21

41

40

42

10

8

27

47

8

18

38

31

68

88

33

9

15

65

2.3a: SLYNTVATLYCVHQR

38

86

53

22

19

37

32

21

41

32

12

12

8

38

19

21

15

33

9

15

65

2.4b: SLYNTVAVLYCVHQR

38

86

53

22

19

37

32

21

38

32

12

12

8

38

19

21

15

33

9

15

65

3.1: SPRTLNAWVKVIEEK

16

61

26

14

60

37

12

65

22

11

16

38

11

12

12

8

11

45

3.2: KVIEEKAFSPEVIPM

26

36

46

13

37

42

32

43

74

33

29

23

33

67

12

63

9

3.3: EKAFSPEVIPMFSAL

24

44

46

27

39

40

37

24

45

43

74

12

21

25

29

27

78

77

42

63

75

23

3.4: SPEVIPMFSALSEGA

24

44

46

39

40

37

24

45

16

21

21

25

9

27

77

42

8

75

4.1a: ATPQDLNMMLNIVGG

24

75

33

15

60

39

39

38

33

45

18

7

32

12

33

43

33

79

4.1b: ATPQDLNTMLNIVGG

24

75

33

15

57

39

39

38

33

45

18

7

32

12

33

43

33

79

4.2: QDLNMMLNIVGGHQA

14

75

37

20

30

29

45

8

9

12

43

11

79

4.3: MMLNIVGGHQAAMQM

12

42

42

12

34

15

32

38

12

11

7

11

13

5.1: SNPPIPVGDIYKRWI

44

36

46

12

17

12

57

43

21

16

54

66

10

13

55

11

13

10

12

57

5.2: GDIYKRWIILGLNKI

16

75

35

59

12

17

31

52

66

39

54

72

63

73

21

7

85

16

9

56

80

20

5.3: KRWIILGLNKIVRMY

36

75

56

44

78

12

23

25

8

19

46

8

63

9

81

81

100

27

5.4a: LGLNKIVRMYSPVSI

36

44

42

8

6

23

25

7

16

46

24

15

9

9

81

42

27

5.4b: LGLNKIVRMYSPTSI

36

44

42

8

6

23

25

7

16

46

24

8

9

9

81

42

27

5.5a: RMYSPVSILDIKQGP

24

66

28

37

43

42

39

30

33

62

32

16

31

10

5.5b: RMYSPTSILDIKQGP

24

66

28

37

43

42

39

30

33

62

32

16

31

10

  1. The percentage of the maximum binding of any allele belongs to a HLA class I serologic specificity analyzed is reported for all the designed peptides. HLA class I serologic specificities are grouped per HLA locus (HLA-A, -B, -C). Peptides are listed on the left and numbered according to the area of GAG protein (see Fig. 1). Peptides shared the same base sequence are listed with the same number followed by a different letter. Prediction values below 5% are indicated with a dot, between 5–29% are reported with normal character, between 30–49% are underlined, higher than 50% of the maximum binding are bolded.